Listen in as Drs Michael Wechsler and Geoffrey Chupp discuss real-world examples of how they use precision medicine in their own clinics to treat moderate to severe asthma.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969685). The topics and discussions are planned, produced, and reviewed independently of the advertiser. This podcast is intended only for US healthcare professionals.

Resources

Theophylline (Rx) https://reference.medscape.com/drug/theo-24-theochron-theophylline-343447

Merged Affinity Network Association Clustering: Joint Multi-Omic/Clinical Clustering to Identify Disease Endotypes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195153/

How Is the Type 2 (T2 High) Subtype of Asthma? https://www.medscape.com/answers/137501-198413/how-is-the-type-2-t2-high-subtype-of-asthma

Targeting Interleukins to Treat Severe Asthma https://www.medscape.com/viewarticle/771133_4

Asthma Workup https://emedicine.medscape.com/article/296301-workup

ImmunoCAP for IgE-Mediated Hyperreactivity Analysis https://www.bioagilytix.com/immunocap-platform-for-immunogenicity-testing/

Bronchiectasis https://emedicine.medscape.com/article/296961-overview

T-Helper Type 2–Driven Inflammation Defines Major Subphenotypes of Asthma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742757/

Efficacy and Safety of Tralokinumab in Patients With Severe Uncontrolled Asthma: A Randomised, Double-blind, Placebo-Controlled, Phase 2b Trial https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(15)00197-6

Mepolizumab for Prednisone-Dependent Asthma With Sputum Eosinophilia https://www.nejm.org/doi/full/10.1056/nejmoa0805435

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma https://www.nejm.org/doi/full/10.1056/nejmoa0808991

Effect of Azithromycin on Asthma Exacerbations and Quality of Life in Adults With Persistent Uncontrolled Asthma (AMAZES): A Randomised, Double-blind, Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31281-3/fulltext

A Randomized, Open-Label, Pragmatic Study to Assess Reliever-Triggered Inhaled Corticosteroid in African American/Black and Hispanic/Latinx Adults With Asthma: Design and Methods of the PREPARE Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130188/

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study https://clinicaltrials.gov/ct2/show/NCT04129931

Drs Michael Wechsler and Mario Castro discuss precision medicine for moderate to severe asthma and the past, present, and future of clinical trials.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969686). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) Network https://preciseasthma.org/preciseweb/

Asthma https://emedicine.medscape.com/article/296301-overview

The Many 'Buckets' of Severe Asthma: Moving Toward Personalized Managements https://www.jaci-inpractice.org/article/S2213-2198(17)30379-3/pdf

What is Fractional Exhaled Nitric Oxide (FeNO) in Pulmonary Function Testing?https://www.medscape.com/answers/303239-77907/what-is-fractional-exhaled-nitric-oxide-feno-in-pulmonary-function-testing

Periostin is a Systemic Biomarker of Eosinophilic Airway Inflammation in Asthmatic Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626285/

Asthma Workup Approach Considerations https://emedicine.medscape.com/article/296301-workup

PrecISE: Precision Medicine in Severe Asthma: An Adaptive Platform Trial With Biomarker Ascertainment https://www.jacionline.org/article/S0091-6749(21)00352-3/fulltext

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma https://www.nejm.org/doi/full/10.1056/NEJMoa1613125

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study https://clinicaltrials.gov/ct2/show/NCT04129931

Designing Clinical Trials to Address the Needs Of Childhood And Adult Asthma: The National Heart, Lung, and Blood Institute's AsthmaNet https://www.jacionline.org/article/S0091-6749(13)01638-2/pdf

Severe Asthma Research Program http://www.severeasthma.org/

Airways Clinical Research Centers https://www.lung.org/research/airways-clinical-research-centers

Lung Health Cohort Study: Making History https://www.lung.org/research/lung-health-cohort-study

Drs Wechsler and Akuthota discuss novel therapies in severe asthma treatment, including precision medicine, biomarkers, and new biologic agents.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969688). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Omalizumab https://reference.medscape.com/drug/xolair-omalizumab-343444

Mepolizumab https://reference.medscape.com/drug/nucala-mepolizumab-1000034

Bronchial Thermoplasty https://emedicine.medscape.com/article/2094272-overview

Eosinophilic Asthma and Sputum Eosinophilia https://www.webmd.com/asthma/eosinophilic-asthma-defined

Role of T2 Inflammation Biomarkers in Severe Asthma https://reference.medscape.com/medline/abstract/26574724

Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry https://linkinghub.elsevier.com/retrieve/pii/S2213-2198(21)00311-1

Dupilumab Prescribing Information https://www.regeneron.com/downloads/dupixent_fpi.pdf

FDA Approves Cinqair to Treat Severe Asthma https://www.fda.gov/news-events/press-announcements/fda-approves-cinqair-treat-severe-asthma

Benralizumab https://reference.medscape.com/drug/fasenra-benralizumab-1000213

Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome) https://emedicine.medscape.com/article/333492-overview

Hypereosinophilic Syndrome https://emedicine.medscape.com/article/202030-overview

Anti-IL-5 Therapy in Patients With Severe Eosinophilic Asthma – Clinical Efficacy and Possible Criteria for Treatment Response https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0689-2

Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-blind, Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60988-X/fulltext

Allergic and Environmental Asthma https://emedicine.medscape.com/article/137501-overview

FDA Approves Maintenance Treatment for Severe Asthma https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma

Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma https://www.nejm.org/doi/full/10.1056/NEJMoa2034975

Efficacy and Safety of Itepekimab in Patients With Moderate-to-Severe Asthma https://www.nejm.org/doi/10.1056/NEJMoa2024257

The Targeted Eosinophil-Lowering Effects of Dexpramipexole in Clinical Studies https://www.sciencedirect.com/science/article/abs/pii/S107997961630328X

CRTH2 Antagonists in Asthma: Current Perspectives https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733922

Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) https://preciseasthma.org/preciseweb/

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype https://clinicaltrials.gov/ct2/show/NCT04718389